A prototype non-invasive blood glucose level measurement optical device (NI-BGL-MOD) has been developed. The NI-BGL-MOD uses a discrete Fourier transform (DFT) method and a fast artificial neural network algorithm to optimize device performance. The appropriate light-emitting diode for the sensory module was selected based on near-infrared spectrophotometry of a blood glucose model and human blood. DFT is implemented in an analog-to-digital converter module. An in vitro trial using the blood glucose model along with a clinical trial involving 110 participants were conducted to evaluate the performance of the prototype. The root-mean-square error of the prototype was 10.8 mg/dl in the in vitro trial and 3.64 mg/dl in the clinical trial, which is lower than the ISO-15197:2016 mandated value of 10 mg/dl. In each trial, consensus error grid analysis indicated that the measurement error was within the safe range. The sensitivity and specificity of the prototype were 0.83 (0.36, 1.00) and 0.90 (0.55, 1.00) in the in vitro trial and 0.81 (0.75, 0.85) and 0.83 (0.78, 0.87) in the clinical trial, respectively. In general, the proposed NI-BGL-MOD demonstrated good performance than gold-standard measurement. Key words: Non-invasive blood glucose measurement, optical device, discrete Fourier transform, multi-formulatric regression, fast artificial neural network

This content is only available via PDF.

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.